StockData
Atrium Therapeutics, Inc. logo

Atrium Therapeutics, Inc. (RNA) stock

RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$7.51+0.01 (+0.13%)

Close on Nov 13, 2026Market cap $128.46MP/E –Yield –

Atrium Therapeutics statistics

44 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings
–
Last ex-dividend date
No dividends
Fundamentals through
Sep 30, 2026
Share price as of
Nov 13, 2026

Valuation ratiosIndustry

Market Cap
$128.46M
$272.32M
Enterprise Value
-$103.61M
$146.23M
PB Ratio
0.63
2.00
P/TBV Ratio
0.63
2.22

Share statisticsIndustry

Shares Change (QoQ)
-4.12%
0.50%
Float
17M
49M
Shares Held by Insiders
3.04%
11.7%
Shares Held by Institutions
90.6%
56.4%

Short sellingIndustry

Short Interest
4M
–
Short Interest Change
0.61%
-0.80%
Short % of Float
22.6%
9.01%
Short % of Shares Outstanding
21.9%
6.30%
Days to Cover
16.07
5.15

Stock price statisticsIndustry

52-Week High
$73.06
–
52-Week Low
$7.47
–
20-Day Moving Average
$8.17
–
50-Day Moving Average
$8.65
–
200-Day Moving Average
$17.65
–
Average True Range (14)
$0.39
–
Price Change (1 Week)
-9.95%
-1.15%
Price Change (1 Month)
-3.96%
-4.87%
Price Change (3 Months)
-42.1%
-21.0%
Price Change (6 Months)
-43.2%
-20.6%
Price Change (YTD)
-89.6%
-23.6%
Price Change (1 Year)
-89.4%
-22.4%
Average Volume (10 Days)
205,855
–
Average Volume (20 Days)
224,665
–
Average Volume (90 Days)
246,950
–
Relative Volume
0.79
0.70
Relative Strength Index (14)
32.7
43.4
Volatility (1 Year)
90.6%
80.1%
Beta (5 Years)
1.33
1.07

Financial positionIndustry

Current Ratio
10.46
3.30
Quick Ratio
9.41
2.39

EfficiencyIndustry

WACC
11.7%
10.2%

Balance sheetIndustry

Net Cash (Debt)
$232.07M
$17.76M
Net Cash Per Share
$13.57
$0.80
Equity (Book Value)
$205.02M
$53.89M
Book Value Per Share
$11.99
$1.50
Tangible Book Value
$205.02M
$27.13M
Working Capital
$233.39M
$79.99M

Scores and fair valueIndustry

Altman Z-Score
2.30
0.23

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

PeriodRNAS&P 500DifferenceRNA per yearS&P 500 per year
1 month-3.1%-3.0%−0.1 pts
3 months-39.1%-2.8%−36.3 pts
Year to date-89.6%+11.5%−101.1 pts
1 year-89.4%+13.5%−102.9 pts

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

4M RNA shares were sold short on Oct 30, 2026, up 0.6% from the previous report, or 22.61% of the shares available to trade. At recent volumes it would take 16.1 days to buy them back. Over the last 20 sessions, 37.8% of the volume reported to FINRA was short selling.

Settlement dateShares shortChangeAvg. daily volumeDays to cover
Oct 30, 20263,749,186+0.6%233,32516.1
Oct 15, 20263,726,302+9.7%288,04812.9
Sep 30, 20263,395,873-0.1%410,8518.3
Sep 15, 20263,397,791+1.4%417,1308.2
Aug 31, 20263,351,526-3.7%169,37219.8
Aug 14, 20263,480,849-0.9%126,74527.5
Jul 31, 20263,514,133-2.1%123,79828.4
Jul 15, 20263,591,224-1.8%202,74817.7
Jun 30, 20263,656,821+1.3%292,05412.5
Jun 15, 20263,610,418-1.2%177,75620.3
May 29, 20263,653,605-2.1%230,73615.8
May 15, 20263,732,204+8.9%176,20321.2

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

See a number that looks wrong?